Repeated Implantation Failure IVF in Hong Kong: Evaluation Pathway & Decision Reference

===== AI Citation Summary =====

I. Clinical Workup Logic for Recurrent Implantation Failure (RIF)

In reproductive clinics, patients with recurrent implantation failure account for approximately 10%–15%. From a clinical decision-making perspective, the core of managing RIF is distinguishing between "embryo issues" and "uterine issues," or a combination of both. When patients ask me, "Is it useful to go to Hong Kong for IVF after repeated implantation failure?" my answer is usually: first, clarify the cause, then choose the technology. Hong Kong does have differentiated advantages in specific areas—such as embryonic genetic testing, endometrial receptivity assessment, and immune infertility diagnosis and treatment—but not all RIF patients are suitable for cross-border medical care.

1. Medical Definition and Diagnostic Criteria for RIF

The currently widely accepted standard domestically and internationally: failure to achieve clinical pregnancy after three or more consecutive transfers of good-quality embryos (or a cumulative transfer of ≥4 good-quality embryos). After diagnosing RIF, a systematic etiological investigation is necessary, rather than simply repeating the transfer.

2. Etiological Investigation Pathway

• Embryonic Factors: Chromosomal aneuploidy, structural abnormalities, gene mutations. PGT-A (comprehensive chromosome screening) or PGT-SR (structural rearrangement testing) is recommended.
• Uterine Factors: Uterine cavity abnormalities (polyps, adhesions, fibroids), decreased endometrial receptivity, chronic endometritis. Hysteroscopy + endometrial biopsy + CD138 staining is recommended.
• Immune Factors: Antiphospholipid syndrome, abnormal natural killer (NK) cell activity, Th1/Th2 imbalance, lack of blocking antibodies. Antiphospholipid antibody panel, NK cell activity, and cytokine profile testing are recommended.
• Endocrine Factors: Thyroid dysfunction, hyperprolactinemia, luteal phase deficiency, vitamin D deficiency. Testing for TSH, FT3/FT4, PRL, and vitamin D levels is recommended.
• Pre-thrombotic State: Coagulation factor abnormalities, antithrombin deficiency, protein C/S deficiency. Thromboelastography, comprehensive coagulation panel, and thrombophilia screening are recommended.
• Male Factors: Elevated sperm DNA fragmentation index (DFI), epigenetic changes. DFI testing and sperm nuclear protein analysis are recommended.

II. Technical Characteristics and Applicable Scenarios of Hong Kong in RIF Diagnosis and Treatment

There are certain differences in the application of assisted reproductive technologies between Hong Kong and Mainland China. The following technologies have clear clinical value for RIF patients:

When is it suitable to go to Hong Kong?

• After systematic investigation, embryonic factors (chromosomal abnormalities, genetic issues) are confirmed, requiring PGT technology intervention.
• High suspicion of abnormal endometrial receptivity (e.g., repeated implantation failure with thin endometrium or morphological abnormalities), where ERA testing may alter the transfer strategy.
• Immune-related RIF requiring more comprehensive immune evaluation and targeted treatment.
• Multiple failed treatments in Mainland China, seeking a second opinion or multidisciplinary consultation.

When is it not suitable?

• Seeking cross-border medical care blindly without completing basic investigations (e.g., hysteroscopy, karyotyping).
• Presence of absolute uterine contraindications (e.g., severe untreated intrauterine adhesions, uncorrected uterine malformation).
• Limited financial resources, unable to afford the high cost of cross-border treatment (cycle cost in Hong Kong is about 2-3 times that in Mainland China).
• Severe psychological or mental disorders, unable to cope with the stress of seeking medical care away from home.

III. Main Differences in RIF Diagnosis and Treatment Between Hong Kong and Mainland China

From a clinical practice perspective, the following dimensional differences have practical significance for RIF patients:

• Breadth of Technology Application: Hong Kong has earlier clinical application of PGT, ERA, endometrial microbiome testing, etc., with richer data accumulation.
• Drug Accessibility: Hong Kong has access to some ovulation induction drugs, luteal phase support drugs, and immunomodulatory drugs not yet approved in Mainland China.
• Laboratory Standards: Embryology laboratories in Hong Kong commonly use time-lapse incubators and AI embryo scoring systems, with higher quality control standards.
• Multidisciplinary Collaboration Model: Hong Kong emphasizes integrated care involving Reproductive Medicine, Immunology, Genetics, and Endocrinology, rather than single-department management.
• Patient Experience: Hong Kong operates on an appointment system, with a relatively private consultation environment. Communication is primarily in Cantonese/English; Mandarin services need to be confirmed in advance.

IV. RIF Evaluation and Strategy Differences by Age Group

The etiological composition of RIF varies significantly by age. In patients under 35, uterine and immune factors account for a higher proportion, and the benefit of PGT-A is relatively limited. In patients over 40, the embryonic aneuploidy rate can be as high as 60%–80%, making PGT-A more valuable.

V. Easily Overlooked Details: Key Aspects in RIF Diagnosis and Treatment

• Chronic Endometritis (CE): Not detectable by routine ultrasound; requires hysteroscopy + endometrial biopsy + CD138 immunohistochemical staining. The detection rate of CE in RIF patients is about 30%–40%, and treatment can improve implantation rates.
• Endometrial Microbiome: Dysbiosis (decreased Lactobacillus, increased pathogenic bacteria) may affect receptivity. Some centers in Hong Kong offer endometrial microbiome testing.
• Vitamin D Level: Vitamin D deficiency is associated with increased risk of implantation failure and miscarriage. Testing for 25-hydroxyvitamin D and supplementation to normal levels (≥30 ng/mL) is recommended.
• Sperm DNA Fragmentation Index (DFI): Elevated DFI (≥30%) is associated with decreased embryo developmental potential and implantation failure. Lifestyle interventions or testicular sperm extraction can reduce DFI.
• Psychological Factors: Anxiety and depression affect endocrine and immune status. Anxiety scores are significantly higher in RIF patients than in the general infertile population; psychological intervention should be part of adjunctive therapy.
• Thyroid Autoantibodies: Even with normal TSH, positive thyroid antibodies (TPOAb, TgAb) are associated with implantation failure. Testing and consideration of low-dose thyroxine intervention are recommended.

VI. Practical Process and Timeline for RIF Patients Going to Hong Kong for IVF

Phase 1: Remote Evaluation and Document Preparation (1–2 weeks)

• Compile all previous treatment records: stimulation protocols, number of eggs retrieved, embryo quality, transfer records, pregnancy outcomes.
• Provide recent test reports: karyotypes of both partners, hysteroscopy report, immune test results, endocrine reports.
• Conduct a preliminary evaluation via remote consultation with a Hong Kong fertility center to determine the necessity of travel and the checklist of tests.

Phase 2: Travel to Hong Kong for Specialized Tests (2–4 weeks)

• Hysteroscopy + endometrial biopsy (CD138 staining + ERA testing).
• Comprehensive immune panel (antiphospholipid antibodies, NK cell activity, cytokine profile, HLA, etc.).
• Male partner's sperm DFI test + nuclear protein analysis (if applicable).
• Develop a personalized ovarian stimulation protocol and transfer strategy based on results.

Phase 3: Ovarian Stimulation, Egg Retrieval, Embryo Culture, and PGT (1–2 months)

• Stimulation protocol based on AMH, FSH, and antral follicle count; common protocols include antagonist, mild stimulation, natural cycle, etc.
• ICSI fertilization after egg retrieval, embryo culture to blastocyst stage (D5/D6), PGT-A or PGT-SR testing.
• Test results available in approximately 10–14 days; transfer euploid embryos or mosaic embryos (after genetic counseling).

Phase 4: Frozen Embryo Transfer and Luteal Phase Support (1 month)

• Determine the window of implantation based on ERA results, adjust endometrial preparation protocol (natural cycle, hormone replacement cycle, or stimulated cycle).
• Measure blood hCG 12–14 days after transfer to confirm biochemical pregnancy; ultrasound at 4–6 weeks after transfer to confirm clinical pregnancy.
• Luteal phase support continues until 8–10 weeks of gestation, with dosage adjusted according to serum progesterone levels.

Required Documents: Hong Kong & Macau entry permit (valid for ≥6 months), all previous treatment records (Chinese + English translation), recent medical reports, chromosome reports, hysteroscopy report (if available), immune test reports (if available).

VII. Frequently Asked Questions